Navigation Links
Genetic Mutation That Makes Common Cancers Resistant to Drugs Identified

Researchers from Eli Lilly and Company and the Phoenix-based Translational Genomics Research Institute (TGen) have identified the genetic mutation that may alter tumour cell proliferation, and make them resistant to certain types of therapies.

The researchers say that they found a recurring mutation of the gene AKT1 in breast, colorectal, and ovarian cancers.

The AKT pathway is among the most commonly activated cellular pathways in human cancers and members of this pathway are among the most frequently targeted for new cancer drug discovery efforts.

The activation of this pathway results in cancer cell growth and cell survival, according to the background information in an article published in an advanced online publication of Nature magazine.

The researchers have for the first time found evidence of direct mutation of AKT1 in clinical samples of human cancer tumours.

"This discovery is a seminal finding in cancer biology that confirms AKT1 as an oncogene in breast, colorectal and ovarian cancer. The mutation alters the electrostatics of binding pocket in the pleckstrin homology domain, the portion of the enzyme that docks with phospholipids on the cell membrane," said Dr. Kerry L. Blanchard, Executive Director, Discovery Biology Research, Eli Lilly and Company.

During the study, the researchers analysed 150 tumour samples from patients with either breast, colorectal or ovarian cancer, and found that eight per cent of breast, six per cent of colorectal and two per cent of ovarian tumours had the AKT1 mutation.

"Recently, molecular features such as the AKT1 mutation are beginning to change drug development efforts. This discovery adds to the short but growing list of molecular features that may help guide both current and future cancer drug development," said Dr. John Carpten, Senior Investigator and Director of TGen's Integrated Cancer Genomics Division and th
'"/>




Page: 1 2

Related medicine news :

1. Genetic Dentistry: Your Dentist may be able to grow you a new set of Teeth.
2. Genetic influence in menopause
3. Genetics and cholesterol levels
4. Genetics helps in attacking cancer
5. Genetic disorder related with sleep patterns
6. Genetic innovation
7. Genetic tests for cancer
8. Genetic indicates memory
9. Genetic mutation to the fountain of youth discovered
10. Genetic differences found between Male and Female brains
11. Alcoholism Influenced By Both Genetics & Family Environment
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...ng to India's health sector with an approval of $6... Tuesday.// "Three projects totalling $662 million...w been approved by the board of executive director...ance ministry statement said. The approval of the...
...s of a Jharkhand girl who complained that she wept...tute of Medical Science (AIIMS) here Wednesday.// ...rkhand, has been complaining of stones in her tear...he was brought to the capital Tuesday for treatmen...
...ed by a pill according to European researchers. Th...owed the effectiveness of the Grazax allergen tabl... treated with allergy shots. Allergies are a resul... to a normally harmless substance, such as dust mi...
...a controversial licensing scheme. According to it,...ucts// will be permitted to describe the ailments ...ing homeopathic remedies into the area of licensed...s designed. However, doctors and scientists believ...
Other Medicine News:Health News:Doctors worried about Homeopathic licensing 2
(Date:9/3/2008)...ollow up results from chronically infected Hepatit... data obtained earlier in 2008, - Study is the f...term antiviral effect of therapeutic Hepati...gly support move into a second generation, vaccin...ing through TLR acti...
(Date:9/3/2008)...Company to Discuss Phase 3 Plans with FDA, PRINCE...ics, Inc.,announced today that it successfully co... of the company,s new, innovative low-dose, once-w...rs to by its internal product,code AG-200-15. The ...t its,primary endpoint of ovulation suppression, c...
(Date:9/2/2008)...t. 3 /- Forest Laboratories...A. today announced results from,two global Phase I...ing,inhaled anticholinergic for the treatment of p... (COPD). In both the ACCLAIM/COPD I&II,(AClidinium...oderate to,Severe COPD Patients) studies, once-dai...
(Date:9/2/2008)...Meets Primary Bone Mineral Density and Secondary E...Company to Host Conference Call and Webcast Wednes...am ET / 5:30 am PT, SAN DIEGO, Sept. 2 /PRNewswir...aq: NBIX ) today announced positive safety and ef...ial using its proprietary, orally-active,nonpeptid...
Breaking Medicine Technology:Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6A tricky tumor virus 9695 1A tricky tumor virus 9695 2Just hours apart 2 brothers undergo robotic prostate cancer surgery 9693 1Just hours apart 2 brothers undergo robotic prostate cancer surgery 9693 2Relatives who decline organ donations face conflict and guilt 9691 1Relatives who decline organ donations face conflict and guilt 9691 2Relatives who decline organ donations face conflict and guilt 9691 3New gene test for prostate cancer at hand 9689 1New gene test for prostate cancer at hand 9689 2
.../PRNewswire-FirstCall/ --,Nuvelo, Inc. today annou... (R-Spondin1), a secreted protein currently in pre...ecific and potent,stimulator of gastrointestinal (...maged in patients with inflammatory bowel,conditio...is. The,study, entitled "R-Spondin1, A Novel Intes...
...abetes Insulin-Free, WASHINGTON, April 10, 2007 /P... adult stem cell therapy, the Journal of the,Ameri...udy in which,14 of 15 Juvenile Diabetes patients d... an adult stem cell treatment. According,to U.S. R...cant in,that it,s the first attempt at using stem ...
Other Medicine Technology:Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 2Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 3Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 4Newest Adult Stem Therapy Treats Diabetes 2
Recommended for aqueous samples of moderate viscosity and density. Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No cleaning, no greasing. Volume Range (ul)
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL.
Our variable volume Finnpipette Techpette combines form and function in a high performance pipette. Advanced pipetting technology, plus a colour-coded volume range, ensures quality, safety, comfort a
Medicine Products: